Nanopublication: RAKJ3r8SnB

Full identifier: http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RAKJ3r8SnB comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAKJ3r8SnB...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "priftin is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis tb caused by mycobacterium tuberculosis 1 1 priftin is indicated for the treatment of latent tuberculosis infection ltbi caused by m tuberculosis 1 2 see limitations of use 1 1 1 2 priftin a r mycobacterium tuberculosis see dosage and administration 2 1 clinical studies 14 1 limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatment priftin should not be used once weekly in the continuation phase regimen in combination with isoniazid inh in hiv infected patients with active pulmonary tuberculosis because of a higher rate of failure and or relapse with rifampin rif resistant organisms see warnings and precautions 5 3 clinical studies 14 1 priftin has not been studied as part of the initial phase treatment regimen in hiv infected patients with active pulmonary tuberculosis priftin is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by mycobacterium tuberculosis see clinical studies 14 2 limitations of use active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection priftin must always be used in combination with isoniazid as a 12 week once weekly regimen for the treatment of latent tuberculosis infection see dosage and administration 2 2 clinical studies 14 2 priftin in combination with isoniazid is not recommended for individuals presumed to be exposed to rifamycin resistant or isoniazid resistant m tuberculosis" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKJ3r8SnB... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-15T18:15:57.113+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKJ3r8SnB... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKJ3r8SnB... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAKJ3r8SnB... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAKJ3r8SnB...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAKJ3r8SnB... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAKJ3r8SnB...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 15 Jun 2021, 16:15:57 UTC

show references